Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Straight Talk About Cancer Drug Coverage

Jan 01 2011

• By Michael McCaughan

Related Content

ReGen Redux: Does a Troubled Medical Device Review Hold Any Lesson For Drugs?

Oct 01 2009

Icahn Wins Two Seats On Biogen Idec’s Board

Jun 03 2009

Vertex Braces For HCV Combo Paradigm With ViroChem Buyout

Mar 04 2009

When Hard Data Are Sparse, FDA Looks To The Experts

Sep 01 2010

Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows

Sep 01 2010

AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

Jun 04 2009

Greece Lowers Drug Prices By Up To 27 Percent

May 05 2010

Apixaban Study Halted – But It May Not Cause Much Damage To The Program

Dec 01 2010

Dendreon vs. CMS: "Full Coverage" or the CED Solution?

Dec 01 2010

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Dec 13 2010

Bristol's Yervoy Gets A Bigger Advisory Committee Cushion

Dec 08 2010

FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial

Aug 04 2010

CMS Takes A Back Seat to No One When it Comes to Drug Safety

Oct 01 2007

AstraZeneca Acquires KuDOS Pharmaceuticals For $210 Mil.

Dec 23 2005

Open Season at Open Sessions: Benlysta May Presage Resurgence of Public Pressure on FDA Committees

Jan 01 2011

Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies

Jan 01 2011

2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound

Jan 03 2011

Increased Advisory Cmte. Preparation Ahead May Challenge FDA, Sponsors

May 26 2008

Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise

Oct 12 2010

Lilly Partners With Marcadia For Injectable Pens To Treat Hypoglycemia

Jun 29 2010

Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote

Jun 01 2010

Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use

Feb 26 2010

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

Dec 01 2010

Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt

Jun 23 2010

Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses

Apr 01 2010

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

Nov 03 2010

China Boosts Health System Reforms With Expanded National Drug Reimbursement List

Dec 08 2009

Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit

Nov 01 2009

Score One For FDAAA: Uloric Approval Was Clinched By Post-Market Powers

Jul 01 2010

KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?

Jul 20 2009

With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too

Jun 23 2008

With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex

Oct 26 2010

Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

Oct 26 2010

Zortress Approval Delay Caused By Novartis Attempts To Avoid Controlled Trial Of Dosing Regimen

Oct 01 2010

BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business

Oct 01 2010

FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

Jan 01 2010

Biologics Reached Record Share Of Novel Approvals In 2009

Jan 01 2010

FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option

Oct 20 2010

Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD May Be The Culprit

Mar 30 2010

Regulatory And Policy News, In Brief

Nov 22 2010

Gilenya Could Surpass Avonex Market Share, Analysts Say

Nov 10 2010

No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials

Jul 20 2010

HRA’s Efficient <i>Ella</i> Development Strategy Begat FDA’s Efficient NDA Review

Nov 01 2010

REMS 2.0: FDA Refining New Drug Safety Tools

Nov 01 2010

China Releases First Part Of Essential Drug List For Community Health Clinics And Rural Hospitals

Aug 19 2009

Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

Sep 10 2010

Related Companies

Amgen, Inc.

Johnson & Johnson

Additional Topics

Regulation Reimbursement Government Payers BioPharmaceutical

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window